# What’s in your weed? Study finds issues with labelling, tracking cannabis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/whats-in-your-weed-study-finds-issues-with-labelling-tracking-cannabis/ > **Published:** 2026-06-18T17:37:43-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:22:30-04:00 > **Clinical Summary:** Cannabis labeling accuracy gaps affect clinical dosing and patient safety. Learn what clinicians should verify and how to counsel patients. --- ✦ New CED Clinical Relevance #50 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchSafetyIndustryTHCCBDDosing Why This Matters Clinicians need accurate product labeling and composition data to counsel patients about cannabinoid content, potency, and contaminants, which directly affects dosing safety and predictability of therapeutic and adverse effects. Current gaps in tracking and labeling systems mean patients may be consuming products with misrepresented THC/CBD ratios or undisclosed contaminants, increasing risks of adverse events and drug interactions that clinicians cannot anticipate. Without reliable product information, [evidence-based cannabis](https://cedclinic.com/jama-cannabis-review-physician-analysis/) prescribing becomes difficult and patient safety monitoring is compromised. Clinical Summary A Lakehead University study identifies significant gaps between cannabis product labels and actual contents, with new products entering the market at a pace that outstrips regulatory surveillance capacity. The research reveals that labeling discrepancies and inadequate tracking systems create challenges for both quality assurance and pharmacovigilance across the supply chain. These findings have direct implications for clinicians prescribing cannabis, as patients may be receiving products with inaccurate cannabinoid profiles, potency levels, or contaminant information that differs from labeled claims. The mismatch between labeled and actual product composition undermines the ability to counsel patients on expected effects, appropriate dosing, and potential adverse reactions based on verified product information. Clinicians should be aware that patient reports of unexpected cannabis effects may reflect labeling inaccuracies rather than individual variation in response, and should advocate for stronger post-market surveillance and standardized testing requirements. Patients seeking cannabis products should be counseled to verify that their source uses third-party testing and to maintain skepticism about label claims until regulatory oversight catches up with market growth. Dr. Caplan’s Take “We’re seeing a real gap between the speed of product innovation and our ability to verify what’s actually in these products through independent testing, which creates legitimate concerns for patients trying to make informed decisions and for clinicians like me trying to advise them responsibly.” Clinical Perspective 💊 As cannabis products proliferate in legal markets, the gap between product labeling accuracy and actual cannabinoid content represents a meaningful clinical challenge for providers counseling patients about potency, dosing, and consistency. The inability of regulatory surveillance systems to keep pace with new product introduction means clinicians cannot reliably depend on advertised THC or CBD concentrations when assessing patient risk or predicting therapeutic and adverse effects, particularly concerning for vulnerable populations such as adolescents, pregnant patients, or those with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/). While labeling discrepancies alone do not determine clinical outcomes, they compound existing uncertainties around individual variability in [cannabis metabolism](https://cedclinic.com/how-long-does-weed-stay-in-your-system/), concurrent medication interactions, and the limited evidence base for most modern high-potency products. Clinicians should acknowledge these quality control limitations when discussing cannabis with patients, avoid assumptions about product safety based on labels, and consider recommending lower starting doses with careful symptom monitoring, especially for patients new to cannabis or those using it 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20What%27s%20in%20your%20weed%3F%20Study%20finds%20issues%20with%20labelling%2C%20tracking%20cannabis%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59617)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59617)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20What%27s%20in%20your%20weed%3F%20Study%20finds%20issues%20with%20labelling%2C%20tracking%20cannabis%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59617)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.tbnewswatch.com/local-news/whats-in-your-weed-study-finds-issues-with-labelling-tracking-cannabis-12429662](https://www.tbnewswatch.com/local-news/whats-in-your-weed-study-finds-issues-with-labelling-tracking-cannabis-12429662) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).